Skip to main content

News

Media Releases

2018

25.7.2018
HBM Healthcare Investments Quarterly Report June 2018
25.6.2018
Shareholders’ Meeting of HBM Healthcare Investments approved all proposals by the Board of Directors
22.6.2018
High demand by investors for the IPO of the HBM-portfolio company Aptinyx
19.6.2018
Invitation to the 17th Ordinary Shareholders' Meeting incl. amended agenda item 9
13.6.2018
Amended motion of the Board of Directors for agenda item 9
13.6.2018
Amendment to agenda item 9 in the invitation to the 17th Ordinary Shareholders’ Meeting on 25 June 2018
1.6.2018
Invitation to the 17th Ordinary Shareholders' Meeting
1.6.2018
Publication of Annual Report 2017/2018 and Invitation to the Ordinary Shareholders' Meeting
18.5.2018
HBM Healthcare Investments reports a profit of CHF 115.9 million for the 2017/2018 financial year; Portfolio will be enriched with further new investments; Positive outlook for the portfolio allows for a 20 percent increase of the proposed cash…
11.5.2018
Eli Lilly announces tender offer for HBM-Portfolio Company ARMO BioSciences for USD 1.6 billion
3.4.2018
HBM Healthcare Investments increases net asset value per share (NAV) by 11 percent in the 2017/2018 financial year; Net profit of around CHF 115 million expected; Share price rises by 34 percent
29.3.2018
Another successful IPO from HBM Healthcare Investments' portfolio: Homology Medicines raises USD 144 million
15.2.2018
HBM Healthcare Investments portfolio company, TandemLife, to be acquired for up to USD 250 million in cash
29.1.2018
Successful IPO of HBM-Portfolio Company ARMO BioSciences
25.1.2018
A strong third quarter further extended HBM Healthcare Investments’ profit for the first nine months of the 2017/2018 financial year to a total of CHF 85.6 million
3.1.2018
Delightful 2017 for HBM Healthcare Investments with 26% value increase of the NAV and 40% gain on the share price

2017

5.12.2017
CSL and HBM-Portfolio Company Vitaeris Announce Strategic Partnership with Option to Acquire
30.10.2017
Novartis announces tender offer for HBM-Portfolio Company Advanced Accelerator Applications for USD 3.9 billion
25.10.2017
HBM Healthcare Investment Half-Year Report September 2017
24.10.2017
Y-mAbs Therapeutics closes USD 50 million financing round led by HBM Healthcare Investments
6.10.2017
HBM Healthcare Investments announces investment of USD 30 million in Harmony Biosciences
2.10.2017
NAV Key Figures as at 30 September 2017
14.9.2017
Capital reduction completed
25.7.2017
HBM Healthcare Investments Quarterly Report June 2017
30.6.2017
NAV Key Figures as at 30 June 2017
26.6.2017
Shareholders’ Meeting approved all proposals by the Board of Directors
2.6.2017
Publication of Annual Report 2016/2017 and Invitation to the Ordinary Shareholders’ Meeting
2.6.2017
Invitation to the 16th ordinary Shareholders’ meeting
23.5.2017
Bioverativ acquires HBM-portfolio company True North Therapeutics for up to USD 825 million plus assumed cash
16.5.2017
HBM Healthcare Investments generated a profit of CHF 136.8 million for the 2016/2017 financial year and increased net asset value per share by 15.2 percent. Board of Directors proposing an increase in the cash dividend of 30 centimes, to…
27.4.2017
HBM Healthcare Investments commits EUR 20 million in growth capital to Switzerland based Amicus SA
3.4.2017
HBM Healthcare Investments expects to report a net profit of around CHF 136 million for the financial year 2016/2017 – increase of the net asset value per share of around 15 percent
31.1.2017
HBM Healthcare Investments Quarterly Report 2016
27.1.2017
Two IPOs from the HBM Healthcare Investments portfolio increase net asset value per HBM-share by CHF 2.30
3.1.2017
Net Asset Value per HBM-share of CHF 133.43 as at 31 December 2016

2016

28.10.2016
HBM Healthcare Investments Quarterly Report September
18.10.2016
HBM Healthcare Investments invests USD 10 million in True North Therapeutics
4.10.2016
Rückkauf eigener Aktien zum Zweck der Kapitalherabsetzung
4.10.2016
Rachat d’actions propres dans le but d’une réduction de capital (103 KB)
4.10.2016
HBM Healthcare Investments launches a new share buy-back programme
3.10.2016
Net asset value (NAV) of CHF 139.42 as at 30 September 2016
30.9.2016
HBM Healthcare Investments terminates share buy-back programme 2014
7.9.2016
Capital reduction completed
29.7.2016
HBM Healthcare Investments Quarterly Report June 2016
24.6.2016
Shareholders’ Meeting approved all proposals by the Board of Directors
17.6.2016
Paratek Pharmaceuticals Announces Positive Phase 3 Results for its Antibiotic Omadacyline
10.6.2016
Recommended all share merger of Skyepharma and Vectura becomes effective
30.5.2016
Annual Report 2015/2016
30.5.2016
Invitation to the 15th Ordinary Shareholders’ Meeting
30.5.2016
Publication of Annual Report 2015/2016 and Invitation to the Ordinary Shareholders’ Meeting
18.5.2016
HBM Healthcare Investments closes financial year 2015/2016 with earnings of CHF 23 million despite a negative market environment. Unchanged cash dividend of CHF 5.50 per share.
1.4.2016
HBM Healthcare Investments closes financial year 2015/2016 with earnings of CHF 23 million despite pronounced market correction in healthcare sector
16.3.2016
Skyepharma to merge with Vectura Group
15.2.2016
Closing of the sale of Ellipse Technologies to NuVasive
10.2.2016
HBM Healthcare Investments adds cancer immunotherapy company ARMO BioSciences to portfolio
29.1.2016
HBM Healthcare Investments Quarterly Report December 2015
12.1.2016
HBM Healthcare Investments backs Iconic Therapeutics to advance development of a novel, disease modifying approach in retinal diseases
6.1.2016
Sale of Ellipse Technologies to NuVasive for an upfront consideration of USD 380 million and a potential additional milestone payment of USD 30 million in cash boosts net asset value per HBM-share by CHF 9.70 (+6.5%)
4.1.2016
Strong increase of net assets by CHF 208 million in the quarter leads to a new high of the NAV per HBM-share of CHF 149.76 as at 31 December 2015

2015

15.12.2015
Cathay Industrial Biotech to set foundation for further successful corporate development with financing of USD 135 million
23.11.2015
HBM Healthcare Investments participates in CHF 60 million financing of Swiss women’s health company ObsEva
19.11.2015
HBM Healthcare Investments commits to invest USD 10 Million in clinical-stage company Eiger BioPharmaceuticals
12.11.2015
Initial Public Offering of Advanced Accelerator Applications boosts Net Asset Value per HBM share by CHF 5.20 (+4.2%)
30.10.2015
HBM Healthcare Investments Quarterly Report September 2015
1.10.2015
Net asset value (NAV) of CHF 121.12 as at 30 September 2015
28.9.2015
Advanced Accelerator Applications: Detailed Phase 3 Study Results Presented at the European Cancer Congress 2015 Demonstrate that Lutathera® Significantly Improves Progression-Free Survival in Patients with Advanced Midgut Neuroendocrine…
28.9.2015
Advanced Accelarator Applications Results from pivotal Phase 3 NETTER-1 Study
21.9.2015
Initial Public Offering of Nabriva Therapeutics
16.9.2015
Advanced Accelerator Applications’ (AAA) Pivotal Phase 3 NETTER-1 Study of Lutathera® Met Primary Endpoint - Data will be Presented at the European Cancer Congress 2015
15.9.2015
Capital reduction completed
21.8.2015
Raptor Pharmaceuticals Acquires Rights to QuinsairTM
31.7.2015
HBM Healthcare Investments Quarterly Report June 2015
2.7.2015
HBM Healthcare Investments AG has closed the books early and has fixed the issue amount of the combined bond tranches at CHF 100 million
1.7.2015
HBM Healthcare Investments NAV Key Figures as at 30.6.2015
30.6.2015
HBM Healthcare Investments announces the issue of two bond tranches, one with a 6 year and the other with a 8 year term with a minimum issue amount of CHF 50 million each
26.6.2015
Shareholders approved all proposals and recommendations by the Board of Directors
2.6.2015
Shareholders’ Letter June 2015
2.6.2015
Invitation to the 14th ordinary Shareholders’ Meeting on 26 June 2015
13.5.2015
HBM Healthcare Investments closed financial year 2014/2015 with a net profit of CHF 257.5 million - Proposed cash dividend of CHF 5.50 per share
1.4.2015
Net asset value (NAV) per share of CHF 140.60 as at 31 March 2015
30.1.2015
HBM Healthcare Investments Quarterly Report December 2014
16.1.2015
NAV Key Figures as at 15 January 2015 / Comment on the impact of foreign exchange rates
5.1.2015
HBM Healthcare Investments reports substantial value growth in calendar year 2014

2014

3.11.2014
Rückkauf eigener Aktien zum Zweck der Kapitalherabsetzung
3.11.2014
Rachat d’actions propres destiné à réduire le capital-actions
3.11.2014
Rückkauf eigener Aktien zum Zweck der Kapitalherabsetzung
3.11.2014
Paratek Pharmaceuticals completes merger with Transcept Pharmaceuticals
31.10.2014
HBM Healthcare Investments launches share buy-back programme
28.10.2014
HBM Healthcare Investments takes USD 8 million stake in Vascular Dynamics
27.10.2014
Probiodrug accomplishes Initial Public Offering at Amsterdam’s Euronext
16.10.2014
Initial Public Offering of Forward Pharma increases Net Asset Value per share by CHF 2.32
1.10.2014
HBM Healthcare Investments NAV Key Figures as at 30 September 2014
25.7.2014
HBM Healthcare Investments Quarterly Report June 2014
2.7.2014
Paratek Pharmaceuticals signs merger agreement with NASDAQ-listed Transcept Pharmaceuticals
1.7.2014
HBM Healthcare Investments Key Figures as at 30 June 2014
20.6.2014
Shareholders approved all proposals and recommendations by the Board of Directors
17.6.2014
Result from share buy-back through the issue of put-options
27.5.2014
Shareholders´ letter
27.5.2014
Invitation to the 13th Ordinary Shareholders´ Meeting
27.5.2014
Media Release: Invitation to the Ordinary Shareholders´ Meeting
23.5.2014
PTC Therapeutics receives positive opinion from European Medical Agency for TranslarnaTM
22.5.2014
Buy-back of own registered shares for the purpose of capital reduction through the issuance of tradable put options
21.5.2014
HBM Healthcare Investments announces terms of share buy-back involving the issue of put options
20.5.2014
Ophthotech enters into licensing agreement with Novartis – share price rises more than 20% in after-market trading
19.5.2014
HBM Healthcare Investments publishes Annual Report 2013/2014
13.5.2014
HBM Healthcare Investments to end “share buy-back programme 2012”
12.5.2014
HBM Healthcare Investments shareholders participate in outstanding annual result: issue of put options to accelerate share buy-backs and proposal of a cash dividend of CHF 3.00 per share to the Ordinary Shareholders´ Meeting
1.4.2014
Net Asset Value per share of CHF 108.76 as at 31 March 2014
31.3.2014
Skyepharma announces £112 million capital increase and launches tender offer for outstanding bonds
17.2.2014
HBM Healthcare Investments participates with EUR 20 million in financing round of Advanced Accelerator Applications
31.1.2014
Quarterly Report December 2013
13.1.2014
Investment in Intercept with spectacular value increase of 647%
3.1.2014
HBM Healthcare Investments achieves compelling value increase of 65 percent in the calendar year 2013

2013

30.10.2013
HBM Healthcare Investments Quarterly Report September 2013
26.9.2013
Ophthotech IPO increases NAV by CHF 4.96 per share (+6.3%)
24.9.2013
Ophthotech increases price range for IPO to USD 19-20 per share
23.9.2013
Quarterly Report June 2013
23.9.2013
Information on Ophthotech IPO
1.7.2013
Key Figures (NAV, net assets, net result for the quarter) as as 30 June 2013
21.6.2013
Shareholders approved all proposals by the Board of Directors
21.6.2013
PTC Therapeutics completes initial public offering
29.5.2013
Ophthotech secures financing of USD 175 million for phase-III clinical trial of FovistaTM
28.5.2013
Annual Report 2012/2013 and invitation to the ordinary Shareholders’ Meeting
13.5.2013
Invitation to the ordinary Shareholders´ Meeting
2.5.2013
HBM Healthcare Investments achieves net profit of CHF 67 million for the year and proposes a par-value repayment of CHF 1.50 per share to shareholders´ meeting
2.4.2013
Key Figures (NAV, net assets, net result) as at 31.03.2013
21.3.2013
Successful IPO for Enanta Pharmaceuticals
30.1.2013
HBM Healthcare Investments Quarterly Report December 2012

2012

30.10.2012
HBM Healthcare Investments Quarterly Report September 2012
10.9.2012
Rachat d’actions propres destiné à réduire le capital-actions
3.9.2012
HBM Healthcare Investments starts new share buy-back programme
27.7.2012
HBM Healthcare Investments Quarterly Report June 2012
3.7.2012
SkyePharma receives approval for flutiform® in Europe
22.6.2012
Shareholders’ Meeting approved all proposals by the Board of Directors and Management presents confident outlook
13.6.2012
Ophthotech’s novel anti-PDGF combination agent FovistaTM demonstrated superior efficacy over Lucentis® monotherapy in large controlled wet AMD trial
12.6.2012
Basilea enters into global agreement with Stiefel, a GlaxoSmithKline company, for Toctino® (alitretinoin)
1.6.2012
Nabriva Therapeutics signs Agreement for Collaboration and Option for Sale of the Company
29.5.2012
Invitation to the ordinary Shareholders´ Meeting
29.5.2012
Annual Report 2011/2012 and invitation to the ordinary Shareholders´ Meeting
3.5.2012
HBM BioVentures publishes annual results for 2011/12
3.4.2012
HBM BioVentures publishes preliminary results for the fourth quarter and the full financial year 2011/12
22.2.2012
Enanta signs significant collaboration agreement with Novartis for Hepatitis C programme
10.2.2012
HBM Report Shows Strong M&A Activity in the Pharma Sector
9.2.2012
Successful Initial Public Offering of ChemoCentryx
27.1.2012
HBM BioVentures Quarterly Report as at 31 December 2011
27.1.2012
Promising new approach to the treatment of wet age-related macular degeneration
24.1.2012
ChemoCentryx announces details for its planned Initial Public Offering
24.1.2012
Vivacta sold to major pharmaceutical company for USD 90 million
6.1.2012
ChemoCentryx licenses investigational drug for rheumatoid arthritis to GlaxoSmithKline
6.1.2012
Pivotal clinical trial of Lux Biosciences misses endpoint

2011

30.11.2011
PTC Therapeutics signs licensing agreement with Roche for Spinal Muscular Atrophy (SMA) Programme (46 KB) 30.11.2011
31.10.2011
New CFO at HBM BioVentures
31.10.2011
Pacira Pharmaceuticals announces U.S. FDA approval of EXPAREL(TM) for postsurgical pain management
28.10.2011
HBM BioVentures Quarterly Report as at 30 September 2011
6.10.2011
Letter of HBM BioVentures to Basilea Pharmaceutica AG: Request to call an Extraordinary Shareholders Meeting
6.10.2011
Request to call an Extraordinary Shareholders Meeting of Basilea
31.8.2011
HBM BioVentures Investor Information
31.8.2011
Closing of the sale of mtm laboratories to Roche
26.8.2011
Press Release
7.8.2011
Cathay Industrial Biotech discontinues its IPO process
1.8.2011
Cathay Industrial Biotech announces further details for its IPO
26.7.2011
HBM BioVentures Quarterly Report as at 30 June 2011
20.7.2011
Cathay Industrial Biotech, third-largest portfolio position of HBM BioVentures, is planning an IPO
19.7.2011
HBM BioVentures sells mtm laboratories, the biggest private investment in the portfolio
24.6.2011
Shareholders´ meeting approved all proposals by the Board of Directors by a very large majority
31.5.2011
HBM bioVentures: Annual Report 2010/2011 and invitation to the ordinary shareholders´ meeting
31.5.2011
Invitation to the ordinary shareholders meeting
5.5.2011
HBM BioVentures closes the operationally successful financial year 2010/2011 with loss of CHF 56 million owing to the sharp rise of the Swiss franc
14.4.2011
Trade sale of Mpex Pharmaceuticals
1.4.2011
HBM BioVentures: Successful sale of indirect holding in China Health System generates cash inflow of approximately USD 27 million
11.3.2011
Closing of the sale of PharmaSwiss to Valeant
4.2.2011
Pacira Pharmaceuticals finances itself via IPO
1.2.2011
HBM BioVentures realises a profit of EUR 41.9 million through the sale of PharmaSwiss to Valeant
24.1.2011
HBM BioVentures Quarterly Report as at 31 Dezember 2010

2010

26.10.2010
HBM BioVentures Quarterly Report as at 30 September 2010
7.10.2010
HBM BioVentures sells its investment in Sloning
21.9.2010
Successful sale of Asthmatx, a company from HBM BioVentures´ portfolio, to Boston Scientific increases liquidity by CHF 4 million
27.7.2010
HBM BioVentures Quarterly Report as at 30 June 2010
13.7.2010
HBM BioVentures’ largest public investment – Micrus – acquired by Johnson & Johnson
2.7.2010
HBM BioVentures sells USD hedging position at a profit
25.6.2010
Shareholders’ meeting approves all proposals by Board of Directors by large majority; Hans Peter Hasler appointed as new Chairman of the Board of Directors; Astellas, which recently acquired OSI Pharmaceuticals, will retain HBM…
16.6.2010
Interview with Dr Andreas Wicki, CEO of HBM BioVentures
2.6.2010
HBM BioVentures: Annual Report financial year 2009/2010 and invitation to its Shareholders´ meeting
2.6.2010
HBM BioVentures delegates the execution of the share buy-back programme delegated to Bank Sarasin/NZB to avoid interruptions
2.6.2010
HBM BioVentures: Invitation to the 9th Ordinary Shareholders´ Meeting
20.5.2010
HBM BioVentures hedges some of the currency risks
3.5.2010
HBM BioVentures closes successful 2009/2010 financial year with a profit of CHF 66 million
20.4.2010
HBM BioVentures is 96% equity-financed after redemption of the convertible bond
12.3.2010
HBM BioVentures Investor Information
10.2.2010
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMAv
29.1.2010
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA
13.1.2010
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA
4.1.2010
HBM BioVentures sells Ziemer Group investmen
4.1.2010
Major financing round for PTC Therapeutics at 2.2 times the previous valuation

2009

11.12.2009
Successful IPO for China Nuokang
9.12.2009
Financing round for Ophthotech
20.11.2009
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA
30.10.2009
HBM BioVentures Quarterly Report as at 30 September 2009
8.10.2009
Paratek Pharmaceuticals, a portfolio company of HBM BioVentures, signs licence agreement over USD 485 million
2.10.2009
Closing of the successful sale of BRAHMS to Thermo Fisher Scientific
14.9.2009
Successful sale of ESBATech, a Swiss company from HBM BioVentures´ portfolio, to Alcon leads to immediate NAV increase of CHF 1.75 and cash inflow of CHF 18.6 million
4.9.2009
HBM BioVentures Ordinary Shareholders´ Meeting All Board of Directors´ proposals approved with clear majority
26.8.2009
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA
11.8.2009
HBM BioVentures: Invitation to the 8th Ordinary Shareholders´ Meeting
11.8.2009
HBM BioVentures: Agenda for the Shareholders´ Meeting
30.7.2009
HBM BioVentures Quarterly Report as at 30 June 2009
8.7.2009
HBM BioVentures reduces its outstanding Going Public Convertible Bond by CHF 39 million
3.6.2009
HBM BioVentures Annual Report 2008/2009
11.5.2009
HBM BioVentures: letter to shareholders
2.4.2009
HBM BioVentures net asset value as at 31 March 2009
30.1.2009
HBM BioVentures quarterly report as at 31 December 2008

2008

21.11.2008
HBM BioVentures holds over 5% of its own shares
12.11.2008
Sale of private portfolio company Panomics
27.10.2008
HBM BioVentures quarterly report as at 30 September 2008 - stable net asset value (NAV)
9.10.2008
HBM BioVentures holds over 3% of its own shares
30.9.2008
Disclosure of shareholdings in accordance with Articles 9 and 17 of the Federal Act of Stock Exchanges and Securities Trading - SFBC
26.9.2008
Takeover of public portfolio company CryoCath Technologies
24.9.2008
Share buyback - listing advertisement English
24.9.2008
Share buyback - listing advertisement French
22.9.2008
HBM BioVentures launches share buyback programme and resolves to make par value repayments
30.7.2008
HBM BioVentures quarterly report as at 30 June 2008 - private portfolio boosts value
22.7.2008
Significant cooperation agreement for portfolio company PTC Therapeutics
30.6.2008
Annual General Meeting of HBM BioVentures Ltd - all Board of Directors proposals approved
30.6.2008
Capital management measures to boost share appeal
5.6.2008
Successful private portfolio positions reduce negative impact of difficult equity market climate in 2007/2008 financial year
20.5.2008
New financing for the porfolio company PharmaSwiss - positive impact on HBM BioVentures´ net asset value (NAV) of CHF 2.90 per share
2.5.2008
HBM BioVentures realises remaining gains on USD currency hedge positions
11.3.2008
HBM BioVentures realises gains on USD currency hedge positions (
6.2.2008
The first day of trading in HBM BioVentures shares on the SWX Swiss Exchange is 14 February 2008
28.1.2008
HBM BioVentures announces further information of its planned IPO on the SWX Swiss Exchange
14.1.2008
HBM BioVentures to apply for listing on the SWX Swiss Exchange